A recent update of pharmacogenomics in drug-induced severe skin reactions

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 1, 2012, Pages 132-141

  Wei, Chun Yu ^a   Ko, Tai Ming ^a   Shen, Chen Yang ^a   Chen, Yuan Tsong ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Adverse drug reactions; Drug allergic reaction; Genetic polymorphism; Immunotoxicology; Pharmacogenomics; Skin

Indexed keywords

CARBAMAZEPINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA B15 ANTIGEN; HLA DR ANTIGEN; SULFAMETHOXAZOLE;

ALLOTYPE; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DISEASE CONTROL; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; EFFECTOR CELL; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; HAPTEN CARRIER COMPLEX; HUMAN; IMMUNOPATHOGENESIS; KERATINOCYTE; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; PHARMACOGENOMICS; RISK ASSESSMENT; RISK REDUCTION; SKIN; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TARGET ORGAN; TOXIC EPIDERMAL NECROLYSIS;

EID: 84863229185     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-RV-116     Document Type: Review

References (96)

1. Roujeau, J. C., Kelly, J. P., Naldi, L., Rzany, B., Stern, R. S., Anderson, T., Auquier, A., Bastuji-Garin, S., Correia, O., Locati, F., Mockenhaupt, M., Paoletti, C., Shapiro, S., Shear, N., Schöpf, E. and Kaufman, D. W.: Medication use and the risk of stevensjohnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med., 333: 1600-1607 (1995).
2. Bastuji-Garin, S., Rzany, B., Stern, R. S., Shear, N. H., Naldi, L. and Roujeau, J. C.: Clinical classification of cases of toxic epidermal necrolysis, stevens-johnson syndrome, and erythema multiforme. Arch. Dermatol., 129: 92-96 (1993).
3. Barry, M. and Bleackley, R. C.: Cytotoxic t lymphocytes: All roads lead to death. Nat. Rev. Immunol., 2: 401-409 (2002).
4. Pores-Fernando, A. T. and Zweifach, A.: Calcium influx and signaling in cytotoxic T-lymphocyte lytic granule exocytosis. Immunol. Rev., 231: 160-173 (2009).
5. Stinchcombe, J. C. and Griffiths, G. M.: Secretory mechanisms in cell-mediated cytotoxicity. Annu. Rev. Cell Dev. Biol., 23: 495-517 (2007).
6. Catalfamo, M. and Henkart, P. A.: Perforin and the granule exocytosis cytotoxicity pathway. Curr. Opin. Immunol., 15: 522-527 (2003).
7. Stinchcombe, J. C. and Griffiths, G. M.: The role of the secretory immunological synapse in killing by cd8+ ctl. Semin. Immunol., 15: 301-305 (2003).
8. Chung, W. H., Hung, S. I., Yang, J. Y., Su, S. C., Huang, S. P., Wei, C. Y., Chin, S. W., Chiou, C. C., Chu, S. C., Ho, H. C., Yang, C. H., Lu, C. F., Wu, J. Y., Liao, Y. D. and Chen, Y. T.: Granulysin is a key mediator for disseminated keratinocyte death in stevens-johnson syndrome and toxic epidermal necrolysis. Nat. Med., 14: 1343-1350 (2008).
9. van den Broek, M. F. and Hengartner, H.: The role of perforin in infections and tumour surveillance. Exp. Physiol., 85: 681-685 (2000).
10. Andersen, M. H., Schrama, D., Thor Straten, P. and Becker, J. C.: Cytotoxic t cells. J. Invest. Dermatol., 126: 32-41 (2006).
11. Neumann, H., Medana, I. M., Bauer, J. and Lassmann, H.: Cytotoxic t lymphocytes in autoimmune and degenerative cns diseases. Trends Neurosci., 25: 313-319 (2002).
12. Gerull, R., Nelle, M. and Schaible, T.: Toxic epidermal necrolysis and stevens-johnson syndrome: A review. Crit. Care Med., 39: 1521-1532 (2011).
13. Nassif, A., Bensussan, A., Dorothee, G., Mami-Chouaib, F., Bachot, N., Bagot, M., Boumsell, L. and Roujeau, J. C.: Drug specific cytotoxic t-cells in the skin lesions of a patient with toxic epidermal necrolysis. J. Invest. Dermatol., 118: 728-733 (2002).
14. Naisbitt, D. J., Britschgi, M., Wong, G., Farrell, J., Depta, J. P., Chadwick, D. W., Pichler, W. J., Pirmohamed, M. and Park, B. K.: Hypersensitivity reactions to carbamazepine: Characterization of the specificity, phenotype, and cytokine profile of drugspecific t cell clones. Mol. Pharmacol., 63: 732-741 (2003).
15. Chessman, D., Kostenko, L., Lethborg, T., Purcell, A. W., Williamson, N. A., Chen, Z., Kjer-Nielsen, L., Mifsud, N. A., Tait, B. D., Holdsworth, R., Almeida, C. A., Nolan, D., Macdonald, W. A., Archbold, J. K., Kellerher, A. D., Marriott, D., Mallal, S., Bharadwaj, M., Rossjohn, J. and McCluskey, J.: Human leukocyte antigen class i-restricted activation of cd8+ t cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity, 28: 822-832 (2008).
16. Wu, Y., Farrell, J., Pirmohamed, M., Park, B. K. and Naisbitt, D. J.: Generation and characterization of antigen-specific cd4+, cd8+, and cd4+cd8+ t-cell clones from patients with carbamazepine hypersensitivity. J. Allergy Clin. Immunol., 119: 973-981 (2007).
17. Ko, T.M., Chung, W.H., Wei, C.Y., Shih, H.Y., Chen, J.K., Lin, C. H., Chen, Y.T. and Hung, S.I.: Shared and restricted t-cell receptor use is crucial for carbamazepine-induced stevens-johnson syndrome. J. Allergy Clin. Immunol., 128: 1266-1276 (2011).
18. Soghoian, D. Z. and Streeck, H.: Cytolytic cd4(+) t cells in viral immunity. Expert Rev. Vaccines, 9: 1453-1463 (2010).
19. Mucida, D. and Cheroutre, H.: The many face-lifts of cd4 t helper cells. Adv. Immunol., 107: 139-152 (2010).
20. Oh, S., Rankin, A. L. and Caton, A. J.: Cd4+cd25 + regulatory t cells in autoimmune arthritis. Immunol. Rev., 233: 97-111 (2010).
21. Wu, Y., Sanderson, J. P., Farrell, J., Drummond, N. S., Hanson, A., Bowkett, E., Berry, N., Stachulski, A. V., Clarke, S. E., Pichler, W. J., Pirmohamed, M., Park, B. K. and Naisbitt, D. J.: Activation of t cells by carbamazepine and carbamazepine metabolites. J. Allergy Clin. Immunol., 118: 233-241 (2006).
22. Zawodniak, A., Lochmatter, P., Yerly, D., Kawabata, T., Lerch, M., Yawalkar, N. and Pichler, W. J.: In vitro detection of cytotoxic t and nk cells in peripheral blood of patients with various drug-induced skin diseases. Allergy, 65: 376-384 (2010).
23. Yawalkar, N.: Drug-induced exanthems. Toxicology, 209: 131-134 (2005).
24. Wittmann, M. and Werfel, T.: Interaction of keratinocytes with infiltrating lymphocytes in allergic eczematous skin diseases. Curr. Opin. Allergy Clin. Immunol., 6: 329-334 (2006).
25. Takahashi, R., Kano, Y., Yamazaki, Y., Kimishima, M., Mizukawa, Y. and Shiohara, T.: Defective regulatory t cells in patients with severe drug eruptions: Timing of the dysfunction is associated with the pathological phenotype and outcome. J. Immunol., 182: 8071-8079 (2009).
26. Borchers, A. T., Lee, J. L., Naguwa, S. M., Cheema, G. S. and Gershwin, M. E.: Stevens-johnson syndrome and toxic epidermal necrolysis. Autoimmun. Rev., 7: 598-605 (2008).
27. Zhan, Y., Corbett, A. J., Brady, J. L., Sutherland, R. M. and Lew, A. M.: Cd4 help-independent induction of cytotoxic cd8 cells to allogeneic p815 tumor cells is absolutely dependent on costimulation. J. Immunol., 165: 3612-3619 (2000).
28. Vivier, E., Tomasello, E., Baratin, M., Walzer, T. and Ugolini, S.: Functions of natural killer cells. Nat. Immunol., 9: 503-510 (2008).
29. Luci, C. and Tomasello, E.: Natural killer cells: Detectors of stress. Int.J. Biochem. Cell Biol., 40: 2335-2340 (2008).
30. Jonjic, S., Babic, M., Polic, B. and Krmpotic, A.: Immune evasion of natural killer cells by viruses. Curr. Opin. Immunol., 20: 30-38 (2008).
31. Barao, I. and Ascensao, J. L.: Human natural killer cells. Arch. Immunol. Ther. Exp. (Warsz.), 46: 213-229 (1998).
32. Poli, A., Michel, T., Theresine, M., Andres, E., Hentges, F. and Zimmer, J.: Cd56bright natural killer (nk) cells: An important nk cell subset. Immunology, 126: 458-465 (2009).
33. Hayakawa, Y., Huntington, N. D., Nutt, S. L. and Smyth, M. J.: Functional subsets of mouse natural killer cells. Immunol. Rev., 214: 47-55 (2006).
34. Farag, S. S., VanDeusen, J. B., Fehniger, T. A. and Caligiuri, M. A.: Biology and clinical impact of human natural killer cells. Int. J. Hematol., 78: 7-17 (2003).
35. Chaves, P., Torres, M. J., Aranda, A., Lopez, S., Canto, F., Blanca, M. and Mayorga, C.: Natural killer-dendritic cell interaction in lymphocyte responses in hypersensitivity reactions to betalactams. Allergy, 65: 1600-1608 (2010).
36. Kulkarni, S., Martin, M. P. and Carrington, M.: The yin and yang of hla and kir in human disease. Semin. Immunol., 20: 343-352 (2008).
37. Morel, E, Escamochero, S, Cabanas, R, Diaz, R, Fiandor, A and Bellon, T: Cd94/nkg2c is a killer effector molecule in patients with stevens-johnson syndrome and toxic epidermal necrolysis. J. Allergy Clin. Immunol., 125:703-710, 710 e701-710 e708 (2010).
38. Chung, W. H., Hung, S. I., Hong, H. S., Hsih, M. S., Yang, L. C., Ho, H. C., Wu, J. Y. and Chen, Y. T.: Medical genetics: A marker for stevens-johnson syndrome. Nature, 428: 486 (2004).
39. Hung, S. I., Chung, W. H., Liou, L. B., Chu, C. C., Lin, M., Huang, H. P., Lin, Y. L., Lan, J. L., Yang, L. C., Hong, H. S., Chen, M. J., Lai, P. C., Wu, M. S., Chu, C. Y., Wang, K. H., Chen, C. H., Fann, C. S., Wu, J. Y. and Chen, Y. T.: Hla-b*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. USA, 102: 4134-4139 (2005).
40. Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A. M., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., James, I. and Christiansen, F. T.: Association between presence of hla-b*5701, hla-dr7, and hla-dq3 and hypersensitivity to hiv-1 reverse-transcriptase inhibitor abacavir. Lancet, 359: 727-732 (2002).
41. Daly, A. K., Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe'er, I., Floratos, A., Daly, M. J., Goldstein, D. B., John, S., Nelson, M. R., Graham, J., Park, B. K., Dillon, J. F., Bernal, W., Cordell, G. J., Pirmohamed, M., Aithal, G. P. and Day, C. P.: Hla-b*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet., 41: 816-819 (2009).
42. Singer, J. B., Lewitzky, S., Leroy, E., Yang, F., Zhao, X., Klickstein, L., Wright, T. M., Meyer, J. and Paulding, C. A.: A genome-wide study identifies hla alleles associated with lumiracoxib-related liver injury. Nat. Genet., 42: 711-714 (2010).
43. Rabot, M., Tabiasco, J., Polgar, B., Aguerre-Girr, M., Berrebi, A., Bensussan, A., Strbo, N., Rukavina, D. and Le Bouteiller, P.: Hla class i/nk cell receptor interaction in early human decidua basalis: Possible functional consequences. Chem. Immunol. Allergy, 89: 72-83 (2005).
44. Godfrey, D. I., MacDonald, H. R., Kronenberg, M., Smyth, M. J. and Van Kaer, L.: Nkt cells: What's in a name? Nat. Rev. Immunol., 4: 231-237 (2004).
45. Kenna, T., Golden-Mason, L., Porcelli, S. A., Koezuka, Y., Hegarty, J. E., O'Farrelly, C. and Doherty, D. G.: Nkt cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine nkt cells. J. Immunol., 171: 1775-1779 (2003).
46. Thomas, S. Y., Hou, R., Boyson, J. E., Means, T. K., Hess, C., Olson, D. P., Strominger, J. L., Brenner, M. B., Gumperz, J. E., Wilson, S. B. and Luster, A. D.: Cd1d-restricted nkt cells express a chemokine receptor profile indicative of th1-type inflammatory homing cells. J. Immunol., 171: 2571-2580 (2003).
47. Cardell, S., Tangri, S., Chan, S., Kronenberg, M., Benoist, C. and Mathis, D.: Cd1-restricted cd4+ t cells in major histocompatibility complex class ii-deficient mice. J. Exp. Med., 182: 993-1004 (1995).
48. Shimamura, M. and Huang, Y. Y.: Presence of a novel subset of nkt cells bearing an invariant v(alpha)19.1-j(alpha)26 tcr alpha chain. FEBS Lett., 516: 97-100 (2002).
49. Diana, J. and Lehuen, A.: Nkt cells: Friend or foe during viral infections? Eur. J. Immunol., 39: 3283-3291 (2009).
50. Brutkiewicz, R. R., Lin, Y., Cho, S., Hwang, Y. K., Sriram, V. and Roberts, T. J.: Cd1d-mediated antigen presentation to natural killer t (nkt) cells. Crit. Rev. Immunol., 23: 403-419 (2003).
51. Miyake, S. and Yamamura, T.: Nkt cells and autoimmune diseases: Unraveling the complexity. Curr. Top. Microbiol. Immunol., 314: 251-267 (2007).
52. Sakuishi, K., Miyake, S. and Yamamura, T.: Role of nk cells and invariant nkt cells in multiple sclerosis. Results Probl. Cell Differ., 51: 127-147 (2010).
53. Godfrey, D. I., Stankovic, S. and Baxter, A. G.: Raising the nkt cell family. Nat. Immunol., 11: 197-206 (2010).
54. Williams, D. P.: Toxicophores: Investigations in drug safety. Toxicology, 226: 1-11 (2006).
55. Viard, I., Wehrli, P., Bullani, R., Schneider, P., Holler, N., Salomon, D., Hunziker, T., Saurat, J. H., Tschopp, J. and French, L. E.: Inhibition of toxic epidermal necrolysis by blockade of cd95 with human intravenous immunoglobulin. Science, 282: 490-493 (1998).
56. Gaedigk, A., Spielberg, S. P. and Grant, D. M.: Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics, 4: 142-153 (1994).
57. Green, V. J., Pirmohamed, M., Kitteringham, N. R., Gaedigk, A., Grant, D. M., Boxer, M., Burchell, B. and Park, B. K.: Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. Biochem. Pharmacol., 50: 1353-1359 (1995).
58. Qiao, H. L., Yang, J. and Zhang, Y. W.: Specific serum ige levels and fcepsilonribeta genetic polymorphism in patients with penicillins allergy. Allergy, 59: 1326-1332 (2004).
59. Guéant-Rodriguez, R. M., Romano, A., Beri-Dexheimer, M., Viola, M., Gaeta, F. and Gueant, J. L.: Gene-gene interactions of il13 and il4ra variants in immediate allergic reactions to betalactam antibiotics. Pharmacogenet. Genomics, 16: 713-719 (2006).
60. Guglielmi, L., Fontaine, C., Gougat, C., Avinens, O., Eliaou, J. F., Guglielmi, P. and Demoly, P.: Il-10 promoter and il4-ralpha gene snps are associated with immediate beta-lactam allergy in atopic women. Allergy, 61: 921-927 (2006).
61. Guéant-Rodriguez, R. M., Gueant, J. L., Viola, M., Tramoy, D., Gaeta, F. and Romano, A.: Association of tumor necrosis factoralpha -308g> a polymorphism with ige-mediated allergy to betalactams in an italian population. Pharmacogenomics J., 8: 162-168 (2008).
62. Nassif, A., Bensussan, A., Boumsell, L., Deniaud, A., Moslehi, H., Wolkenstein, P., Bagot, M. and Roujeau, J. C.: Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic t cells. J. Allergy Clin. Immunol., 114: 1209-1215 (2004).
63. Naisbitt, D. J., Farrell, J., Wong, G., Depta, J. P., Dodd, C. C., Hopkins, J. E., Gibney, C. A., Chadwick, D. W., Pichler, W. J., Pirmohamed, M. and Park, B. K.: Characterization of drug-specific t cells in lamotrigine hypersensitivity. J. Allergy Clin. Immunol., 111: 1393-1403 (2003).
64. Griem, P., Wulferink, M., Sachs, B., Gonzalez, J. B. and Gleichmann, E.: Allergic and autoimmune reactions to xenobiotics: How do they arise? Immunol. Today, 19: 133-141 (1998).
65. Padovan, E., Bauer, T., Tongio, M. M., Kalbacher, H. and Weltzien, H. U.: Penicilloyl peptides are recognized as t cell antigenic determinants in penicillin allergy. Eur. J. Immunol., 27: 1303-1307 (1997).
66. Pichler, W. J., Beeler, A., Keller, M., Lerch, M., Posadas, S., Schmid, D., Spanou, Z., Zawodniak, A. and Gerber, B.: Pharmacological interaction of drugs with immune receptors: The p-i concept. Allergol. Int., 55: 17-25 (2006).
67. Schmid, D. A., Depta, J. P., Luthi, M. and Pichler, W. J.: Transfection of drug-specific t-cell receptors into hybridoma cells: Tools to monitor drug interaction with t-cell receptors and evaluate cross-reactivity to related compounds. Mol. Pharmacol., 70: 356-365 (2006).
68. Christiansen C. Late-onset allergy-like reactions to x-ray contrast media. Curr. Opin. Allergy Clin. Immunol., 2: 333-339 (2002).
69. Zanni, M. P., Mauri-Hellweg, D., Brander, C., Wendland, T., Schnyder, B., Frei, E., von Greyerz, S., Bircher, A. and Pichler, W. J.: Characterization of lidocaine-specific t cells. J. Immunol., 158: 1139-1148 (1997).
70. Adam, J., Pichler, W. J. and Yerly, D.: Delayed drug hypersensitivity: Models of t-cell stimulation. Br. J. Clin. Pharmacol., 71: 701-707 (2011).
71. Schnyder, B., Mauri-Hellweg, D., Zanni, M., Bettens, F. and Pichler, W. J.: Direct, mhc-dependent presentation of the drug sulfamethoxazole to human alphabeta t cell clones. J. Clin. Invest., 100: 136-141 (1997).
72. Yang, L., Chen, J. and He, L.: Harvesting candidate genes responsible for serious adverse drug reactions from a chemical- protein interactome. PLOS Comput. Biol., 5: e1000441 (2009).
73. Castrejon, J. L., Berry, N., El-Ghaiesh, S., Gerber, B., Pichler, W. J., Park, B. K. and Naisbitt, D. J.: Stimulation of human t cells with sulfonamides and sulfonamide metabolites. J. Allergy Clin. Immunol., 125: 411-418 e4 (2010).
74. Reilly, T. P., Lash, L. H., Doll, M. A., Hein, D. W., Woster, P. M. and Svensson, C. K.: A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J. Invest. Dermatol., 114: 1164-1173 (2000).
75. Roychowdhury, S., Vyas, P. M., Reilly, T. P., Gaspari, A. A. and Svensson, C. K.: Characterization of the formation and localization of sulfamethoxazole and dapsone-associated drug-protein adducts in human epidermal keratinocytes. J. Pharmacol. Exp. Ther., 314: 43-52 (2005).
76. Le Cleach, L., Delaire, S., Boumsell, L., Bagot, M., Bourgault-Villada, I., Bensussan, A. and Roujeau, J. C.: Blister fluid t lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (nk) inhibitory receptors. Clin. Exp. Immunol., 119: 225-230 (2000).
77. Tapia, B., Padial, A., Sanchez-Sabate, E., Alvarez-Ferreira, J., Morel, E., Blanca, M. and Bellon, T.: Involvement of ccl27-ccr10 interactions in drug-induced cutaneous reactions. J. Allergy Clin. Immunol., 114: 335-340 (2004).
78. Locharernkul, C., Loplumlert, J., Limotai, C., Korkij, W., Desudchit, T., Tongkobpetch, S., Kangwanshiratada, O., Hirankarn, N., Suphapeetiporn, K. and Shotelersuk, V.: Carba- mazepine and phenytoin induced stevens-johnson syndrome is associated with hla-b*1502 allele in thai population. Epilepsia, 49: 2087-2091 (2008).
79. Lonjou, C., Thomas, L., Borot, N., Ledger, N., de Toma, C., LeLouet, H., Graf, E., Schumacher, M., Hovnanian, A., Mockenhaupt, M. and Roujeau, J. C.: A marker for stevensjohnson syndrome: Ethnicity matters. Pharmacogenomics J., 6: 265-268 (2006).
80. Mehta, T. Y., Prajapati, L. M., Mittal, B., Joshi, C. G., Sheth, J. J., Patel, D. B., Dave, D. M. and Goyal, R. K.: Association of hla-b*1502 allele and carbamazepine-induced stevens-johnson syndrome among indians. Indian J. Dermatol. Venereol. Leprol., 75: 579-582 (2009).
81. Tassaneeyakul, W., Tiamkao, S., Jantararoungtong, T., Chen, P., Lin, S. Y., Chen, W. H., Konyoung, P., Khunarkornsiri, U., Auvichayapat, N., Pavakul, K., Kulkantrakorn, K., Choonhakarn, C., Phonhiamhan, S., Piyatrakul, N., Aungaree, T., Pongpakdee, S. and Yodnopaglaw, P.: Association between hla-b*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a thai population. Epilepsia, 51: 926-930 (2010).
82. Yang, C. W., Hung, S. I., Juo, C. G., Lin, Y. P., Fang, W. H., Lu, I. H., Chen, S. T. and Chen, Y. T.: Hla-b*1502-bound peptides: Implications for the pathogenesis of carbamazepine- induced stevens-johnson syndrome. J. Allergy Clin. Immunol., 120: 870-877 (2007).
83. Kaniwa, N., Saito, Y., Aihara, M., Matsunaga, K., Tohkin, M., Kurose, K., Furuya, H., Takahashi, Y., Muramatsu, M., Kinoshita, S., Abe, M., Ikeda, H., Kashiwagi, M., Song, Y., Ueta, M., Sotozono, C., Ikezawa, Z. and Hasegawa, R.: Hla-b*1511 is a risk factor for carbamazepine-induced stevens-johnson syndrome and toxic epidermal necrolysis in japanese patients. Epilepsia, 51: 2461-2465 (2010).
84. Kim, S. H., Lee, K. W., Song, W. J., Jee, Y. K., Lee, S. M., Kang, H. R., Park, H. W., Cho, S. H., Park, S. H., Min, K. U. and Chang, Y. S.: Carbamazepine-induced severe cutaneous adverse reactions and hla genotypes in koreans. Epilepsy. Res., 97: 190-197, 2011.
85. Chen, P., Lin, J. J., Lu, C. S., Ong, C. T., Hsieh, P. F., Yang, C. C., Tai, C. T., Wu, S. L., Lu, C. H., Hsu, Y. C., Yu, H. Y., Ro, L. S., Lu, C. T., Chu, C. C., Tsai, J. J., Su, Y. H., Lan, S. H., Sung, S. F., Lin, S. Y., Chuang, H. P., Huang, L. C., Chen, Y. J., Tsai, P. J., Liao, H. T., Lin, Y. H., Chen, C. H., Chung, W. H., Hung, S. I., Wu, J. Y., Chang, C. F., Chen, L., Chen, Y. T. and Shen, C. Y.: Carbamazepine-induced toxic effects and hla-b*1502 screening in taiwan. N. Engl. J. Med., 364: 1126-1133 (2011).
86. Mallal, S., Phillips, E., Carosi, G., Molina, J. M., Workman, C., Tomazic, J., Jagel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F., Hay, P., Nolan, D., Hughes, S., Hughes, A., Ryan, S., Fitch, N., Thorborn, D. and Benbow, A.: Hla-b*5701 screening for hypersensitivity to abacavir. N. Engl.J. Med., 358: 568-579 (2008).
87. Romano, A., De Santis, A., Romito, A., Di Fonso, M., Venuti, A., Gasbarrini, G. B. and Manna, R.: Delayed hypersensitivity to aminopenidllins is related to major histocompatibility complex genes. Ann. Allergy Asthma Immunol., 80: 433-437 (1998).
88. Ozeki, T., Mushiroda, T., Yowang, A., Takahashi, A., Kubo, M., Shirakata, Y., Ikezawa, Z., Iijima, M., Shiohara, T., Hashimoto, K., Kamatani, N. and Nakamura, Y.: Genome-wide association study identifies hla-a*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in japanese population. Hum. Mol. Genet., 20: 1034-1041 (2011).
89. Lonjou, C., Borot, N., Sekula, P., Ledger, N., Thomas, L., Halevy, S., Naldi, L., Bouwes-Bavinck, J. N., Sidoroff, A., de Toma, C., Schumacher, M., Roujeau, J. C., Hovnanian, A. and Mockenhaupt, M.: A european study of hla-b in stevens-johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics, 18: 99-107 (2008).
90. Kim, S. H., Kim, M., Lee, K. W., Kang, H. R., Park, H. W. and Jee, Y. K.: Hla-b*5901 is strongly associated with methazolamide- induced stevens-johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics, 11: 879-884 (2010).
91. Martin, A. M., Nolan, D., James, I., Cameron, P., Keller, J., Moore, C., Phillips, E., Christiansen, F. T. and Mallal, S.: Predisposition to nevirapine hypersensitivity associated with hla- drb1*0101 and abrogated by low cd4 t-cell counts. AIDS, 19: 97-99 (2005).
92. Littera, R., Carcassi, C., Masala, A., Piano, P., Serra, P., Ortu, E., Corso, N., Casula, B., La Nasa, G., Contu, L. and Manconi, P. E.: Hla-dependent hypersensitivity to nevirapine in sardinian hiv patients. AIDS, 20: 1621-1626 (2006).
93. Kaniwa, N., Saito, Y., Aihara, M., Matsunaga, K., Tohkin, M., Kurose, K., Sawada, J., Furuya, H., Takahashi, Y., Muramatsu, M., Kinoshita, S., Abe, M., Ikeda, H., Kashiwagi, M., Song, Y., Ueta, M., Sotozono, C., Ikezawa, Z. and Hasegawa, R.: HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics, 9: 1617-1622 (2008).
94. Hung, S. I., Chung, W. H., Jee, S. H., Chen, W. C., Chang, Y. T., Lee, W. R., Hu, S. L., Wu, M. T., Chen, G. S., Wong, T. W., Hsiao, P. F., Chen, W. H., Shih, H. Y., Fang, W. H., Wei, C. Y., Lou, Y. H., Huang, Y. L., Lin, J. J. and Chen, Y. T.: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics, 16: 297-306 (2006).
95. Man, C. B., Kwan, P., Baum, L., Yu, E., Lau, K. M., Cheng, A. S. and Ng, M. H.: Association between hla-b*1502 allele and antiepileptic drug-induced cutaneous reactions in han chinese. Epilepsia, 48: 1015-1018 (2007).
96. Ikeda, H., Takahashi, Y., Yamazaki, E., Fujiwara, T., Kaniwa, N., Saito, Y., Aihara, M., Kashiwagi, M. and Muramatsu, M.: Hla class i markers in japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia, 51: 297-300 (2010).